vorinostat has been researched along with Cirrhosis in 16 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC) inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ)." | 7.81 | Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. ( Mohan, RR; Sharma, A; Siddiqui, S; Sinha, NR, 2015) |
| "To determine whether daily oral administration of suberoylanilide hydroxamic acid (SAHA; vorinostat) for 5-weeks from the immediate post-injury period after CN injury would rectify CVOD by suppressing cavernosal fibrosis and normalizing HDAC pathway in a rat model of CN crush injury (CNCI) and to compare the results with those obtained using chronic administration of PDE5-inhibitors (a positive control)." | 4.02 | Rectification of cavernosal fibrosis and veno-occlusive dysfunction by administration of suberoylanilide hydroxamic acid in a rat model of cavernosal nerve injury: Comparison with a PDE5 inhibitor. ( Cho, MC; Kim, SW; Lee, J; Son, H, 2021) |
| "We have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC) inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ)." | 3.81 | Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition. ( Mohan, RR; Sharma, A; Siddiqui, S; Sinha, NR, 2015) |
| "This study was undertaken to evaluate the efficacy of co-treatment with suberoylanilide hydroxamic acid (SAHA) and mitomycin-C (MMC) on corneal fibrosis in an in-vivo model." | 3.80 | The efficacy of co-treatment with suberoylanilide hydroxamic acid and mitomycin C on corneal scarring after therapeutic keratectomy: an animal study. ( Kim, SW; Park, WC; Woo, JE; Yoo, YH, 2014) |
| "This study investigated the efficacy and safety of vorinostat, a deacetylase (HDAC) inhibitor, in the treatment of laser-induced corneal haze following photorefractive keratectomy (PRK) in rabbits in vivo and transforming growth factor beta 1 (TGFβ1) -induced corneal fibrosis in vitro." | 3.78 | Vorinostat: a potent agent to prevent and treat laser-induced corneal haze. ( Cowden, JW; Gibson, DJ; Liu, Y; Mohan, RR; Schultz, GS; Sharma, A; Tandon, A; Tovey, JC; Waggoner, MR, 2012) |
| "This study was conducted to evaluate cytotoxicity due to co-treatment with low-dose Mitomycin-C (MMC) and the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA) for glaucoma filtration surgery." | 3.76 | An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with mitomycin-C and a histone deacetylase inhibitor. ( Ahn, HB; Jeung, WJ; Kim, TH; Oh, HC; Park, WC; Rho, JH; Rho, SH; Yoo, YH, 2010) |
| " Suberanilohydroxamic acid (SAHA) however has been proposed to prevent corneal haze without any adverse effects." | 1.62 | Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells. ( Dadachanji, ZV; Das, D; Ghosh, A; Khamar, P; Krishna, L; Kumar, NR; Matalia, H; Mohan, RR; Murugeswari, P; Shetty, R; Subramani, M, 2021) |
| " Additional in vivo SAHA dosing studies with larger sample size are warranted." | 1.43 | Development of a novel in vivo corneal fibrosis model in the dog. ( Bunyak, F; Giuliano, EA; Gronkiewicz, KM; Hamm, CW; Kuroki, K; Mohan, RR; Sharma, A; Teixeira, LB, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, J | 2 |
| Cho, MC | 2 |
| Son, H | 2 |
| Kim, SW | 4 |
| Yang, JS | 1 |
| Liu, P | 1 |
| Liu, JJ | 1 |
| Chu, L | 1 |
| Li, J | 2 |
| Chen, C | 2 |
| Yan, L | 1 |
| Liu, TJ | 1 |
| Chen, H | 1 |
| Hao, DJ | 1 |
| Shetty, R | 1 |
| Kumar, NR | 1 |
| Subramani, M | 1 |
| Krishna, L | 1 |
| Murugeswari, P | 1 |
| Matalia, H | 1 |
| Khamar, P | 1 |
| Dadachanji, ZV | 1 |
| Mohan, RR | 5 |
| Ghosh, A | 1 |
| Das, D | 1 |
| Wang, K | 1 |
| Tang, R | 1 |
| Wang, S | 1 |
| Wang, W | 1 |
| Zhang, K | 1 |
| Li, P | 1 |
| Tang, YD | 1 |
| Vella, S | 1 |
| Conaldi, PG | 1 |
| Cova, E | 1 |
| Meloni, F | 1 |
| Liotta, R | 1 |
| Cuzzocrea, S | 1 |
| Martino, L | 1 |
| Bertani, A | 1 |
| Luca, A | 1 |
| Vitulo, P | 1 |
| Woo, JE | 1 |
| Park, WC | 3 |
| Yoo, YH | 3 |
| Patschan, D | 1 |
| Schwarze, K | 1 |
| Henze, E | 1 |
| Patschan, S | 1 |
| Müller, GA | 1 |
| Sharma, A | 4 |
| Sinha, NR | 1 |
| Siddiqui, S | 1 |
| Gronkiewicz, KM | 2 |
| Giuliano, EA | 2 |
| Kuroki, K | 1 |
| Bunyak, F | 1 |
| Teixeira, LB | 1 |
| Hamm, CW | 1 |
| Wang, Z | 1 |
| Finger, SN | 1 |
| Kwajah, S | 1 |
| Jung, M | 1 |
| Schwarz, H | 1 |
| Swanson, N | 1 |
| Lareu, FF | 1 |
| Raghunath, M | 1 |
| Iyer, A | 1 |
| Fenning, A | 1 |
| Lim, J | 1 |
| Le, GT | 1 |
| Reid, RC | 1 |
| Halili, MA | 1 |
| Fairlie, DP | 1 |
| Brown, L | 1 |
| Kim, TH | 2 |
| Oh, HC | 1 |
| Rho, JH | 2 |
| Ahn, HB | 1 |
| Jeung, WJ | 1 |
| Rho, SH | 2 |
| Tandon, A | 1 |
| Tovey, JC | 1 |
| Waggoner, MR | 1 |
| Cowden, JW | 1 |
| Gibson, DJ | 1 |
| Liu, Y | 1 |
| Schultz, GS | 1 |
| Woo, JM | 1 |
| Lee, DJ | 1 |
| Park, JM | 1 |
| Jeong, WJ | 1 |
16 other studies available for vorinostat and Cirrhosis
| Article | Year |
|---|---|
Restoring erectile function by combined treatment with JNK inhibitor and HDAC inhibitor in a rat model of cavernous nerve injury.
Topics: Animals; Caspase 3; Disease Models, Animal; Erectile Dysfunction; Fibronectins; Fibrosis; Histone De | 2022 |
Suberoylanilide hydroxamic acid attenuates epidural fibrosis via inhibiting myofibroblast differentiation and increasing fibroblast apoptosis.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Epidural Space; Female; Fibr | 2020 |
Rectification of cavernosal fibrosis and veno-occlusive dysfunction by administration of suberoylanilide hydroxamic acid in a rat model of cavernosal nerve injury: Comparison with a PDE5 inhibitor.
Topics: Animals; Disease Models, Animal; Fibrosis; Histone Deacetylases; Impotence, Vasculogenic; Male; Nerv | 2021 |
Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells.
Topics: Adult; Apoptosis; Cells, Cultured; Collagen Type IV; Epithelium, Corneal; Female; Fibrosis; Humans; | 2021 |
SAHA could inhibit TGF-β1/p38 pathway in MI-induced cardiac fibrosis through DUSP4 overexpression.
Topics: Animals; Fibroblasts; Fibrosis; Heart Diseases; Histone Deacetylase Inhibitors; MAP Kinase Signaling | 2022 |
Lung resident mesenchymal cells isolated from patients with the Bronchiolitis Obliterans Syndrome display a deregulated epigenetic profile.
Topics: Adult; Aged; Bronchiolitis Obliterans; Bronchoalveolar Lavage Fluid; Cell Differentiation; Cell Line | 2018 |
The efficacy of co-treatment with suberoylanilide hydroxamic acid and mitomycin C on corneal scarring after therapeutic keratectomy: an animal study.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Survival; Cicatrix; Corneal Diseases; Cytokin | 2014 |
Endothelial autophagy and Endothelial-to-Mesenchymal Transition (EndoMT) in eEPC treatment of ischemic AKI.
Topics: Actins; Acute Kidney Injury; Animals; Autophagy; beta-Galactosidase; Cells, Cultured; Disease Models | 2016 |
Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition.
Topics: Cell Transdifferentiation; Cells, Cultured; Cornea; Corneal Diseases; Corneal Injuries; Fibroblasts; | 2015 |
Development of a novel in vivo corneal fibrosis model in the dog.
Topics: Actins; Animals; Biomarkers; Burns, Chemical; Cornea; Corneal Diseases; Disease Models, Animal; Dogs | 2016 |
Molecular mechanisms of suberoylanilide hydroxamic acid in the inhibition of TGF-β1-mediated canine corneal fibrosis.
Topics: Animals; Cells, Cultured; Cornea; Dogs; Fibrosis; Histone Deacetylase Inhibitors; Hydroxamic Acids; | 2016 |
Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?
Topics: Actins; Anti-Inflammatory Agents; Cell Line; Cell Proliferation; Collagen; Epigenesis, Genetic; Fibr | 2009 |
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats.
Topics: Animals; Desoxycorticosterone; Fibrosis; Heart; Histone Deacetylase Inhibitors; Hydroxamic Acids; Hy | 2010 |
An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with mitomycin-C and a histone deacetylase inhibitor.
Topics: Alkylating Agents; Animals; Apoptosis; Cells, Cultured; Conjunctiva; Drug Therapy, Combination; Epit | 2010 |
Vorinostat: a potent agent to prevent and treat laser-induced corneal haze.
Topics: Actins; Animals; Cells, Cultured; Cornea; Corneal Keratocytes; Corneal Opacity; Dose-Response Relati | 2012 |
Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of rabbit tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery.
Topics: Alkylating Agents; Animals; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Caspase 3; C | 2008 |